ONCY ONCY
Company Profile ↓Company Overview
ONCY (ONCY) is a publicly traded company listed on with a market capitalization of $86.42M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -9.41% |
| 6 Months: | -9.41% |
| 3 Months: | -13.35% |
| 1 Month: | -7.30% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.14 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 43.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 4.89M | 4.17M | 9.94M | 9.65M | 9.28M |
| Operating Income | - | -4.89M | -4.17M | -9.94M | -9.65M | -9.28M |
| EBITDA | - | -4.82M | -4.10M | -9.88M | -9.65M | -9.27M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -4.67M | -4.44M | -10.53M | -8.98M | -9.24M |
| Tax Provision | 11.38K | - | 62.12K | -181.07K | 198.99K | - |
| Net Income | - | -4.67M | -4.51M | -10.35M | -9.18M | -9.24M |
| Diluted EPS | - | -0.06 | -0.05 | -0.10 | - | -0.08 |
| R&D Expense | - | 2.80M | - | - | - | 4.55M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 19.84M | 25.47M | 24.37M | 28.73M |
| Operating Income | - | -19.84M | -25.47M | -24.37M | -28.73M |
| EBITDA | - | -19.55M | -25.17M | -24.08M | -28.66M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -18.24M | -20.85M | -22.00M | -28.68M |
| Tax Provision | - | 61.89K | 73.12K | 90.58K | 79.00K |
| Net Income | - | -18.30M | -20.92M | -22.09M | -28.76M |
| Diluted EPS | - | -0.32 | -0.31 | -0.29 | -0.30 |
| R&D Expense | - | - | - | 15.44M | 13.31M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 27.51M | 29.26M | 14.07M | 7.58M |
| Current Assets | - | 26.29M | 28.78M | 13.15M | 6.84M |
| Cash & Equivalents | - | 8.60M | 26.32M | 11.11M | 5.20M |
| Inventory | - | - | - | - | - |
| Receivables | - | 383.88K | 11.31K | 47.38K | 573.00K |
| Total Liabilities | - | 7.98M | 8.49M | 9.90M | 11.38M |
| Current Liabilities | - | 2.91M | 3.19M | 4.66M | 6.10M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 274.83K | 318.86K | 741.37K | 563.00K |
| Total Equity | - | 19.53M | 20.78M | 4.17M | -3.80M |
| Shares Outstanding | - | 61.33M | 74.42M | 80.02M | 108.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -17.21M | -21.44M | -18.79M | -20.11M |
| Investing Cash Flow | - | -15.03M | 15.24M | -166.53K | -6.00K |
| Financing Cash Flow | - | 8.99M | 24.12M | 4.62M | 14.12M |
| Capital Expenditure | - | -40.52K | -6.03K | -166.53K | -6.00K |
| Free Cash Flow | - | -17.25M | -21.45M | -18.96M | -20.12M |
| Net Change in Cash | - | -23.25M | 17.92M | -14.33M | -6.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -93.7% | -100.7% | -530.0% | 757.0% |
| ROCE % | - | -80.6% | -97.7% | -259.1% | -1,939.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ONCY
Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY) - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPM1RGUGJSVlVJbG9ycTV0T0xncXRIa1k3SXFmYy1tR1RkLU1xM2ozOXRldTEwLXNzcllUZGtaU240ZG5SUkY1cjVZYVRhbllvYTlfZ3FlajdMSWRnUVhaVU9odWlEdEF6a1JtYkd2NzJnUVVfMGc5OEd5U0phUnhmMXdoZDRKT0hCYW5uOX…
Investigational anal cancer therapy posts 30% response rate - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPOE00NFN5ZHdjY2JNOXQ2T2RFcEJaQWF3VDdHbndBazBKUnVWVEJVbnJmcFRaUHptRk5FS1FMaEVyLWRoaXVuTWc1d19HUEY5VnYycExadmppdmRuSDFWUXVBa3NZUkdOQVhCLVN5b1B4bHVWSU1za3M2VU13enl1REFIZmozdjV0dmUwaT…
Oncolytics Biotech (NASDAQ:ONCY) Trading Up 0.2% - Time to Buy? - MarketBeat
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPdXUxc2VDOWR1cnpZTmwwX09URFNBZDFZTnlpNF95ZlE1UnVLdDFkRVlLSjhyMzhSMUZicnVLaGhyd3BSY2NQb0hHalZzd2FHcmVTdndVOC1PbjZqLWFtX0J6Y2ZFV2dqOU9ZWHM3Z2p1c0Z1V2tUTU51c2FIMXZKLVIwTG9Icm0zdmZFbU…
$ONCY stock is up 13% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOcnV4MUtxbWN6aFZtZi1DWUl1LXR5a01oZTZpNW1TR3Jla0wzMlZJZGpRVUJlWXlxQVNabFpzX2RpS1FNa3B6UDF4YzBMUWtuU1BETUllWElOWTRGaDFMV1JkWkZCQzFtY3drMEhsZHZwbE9IWkloazhnVjF2anFvYTE3R2swNjFxc0NzRk…
ONCY Stock Surged Today – Here’s What Securing A Key Immunotherapy Patent Means For Oncolytics - Stocktwits
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQUVNWV0tmYUo5SWlkNjNSZ3JMRjNZZXptbk9ELXAtYVJSNmhiYWh5Wl80VXZNUDRyY1QwRXh1OUZvbVZSZ2EydC1iQ0lWOVRmNTB5S3BuLUUtN18yM1p5RTFvWHNKWUR2Z0NKaGpZU1lTT0ZtTFBuVnQtV2UwZzBXUFpKQjlXRHlEUzkyZ3…
Is Oncolytics Biotech (ONCY) Price Reset Creating A Long Term Opportunity? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxNY3ZUdmNsQW95SDg0azJQdDE4NE5CYmVabEgzYS1EaVVYRGZhcXFvWmJFdVNTam9ScHVhVkdDM09IR0h5MmR5VFNwZ280QTkwRFdOeU5tNFJfcWw5eWdZY2JrdE9lUXppN25TbFlucHZaQTliWmx3SFNodk5zczZQVkQ5WkhEbGY2cXpsbn…
ONCY — Frequently Asked Questions
What is the current share price of ONCY?
As of 2026-08-05 17:25 PDT, ONCY trades at $0.80 on NASDAQ/NYSE. Its 52-week range is $0.75 to $1.42.
What is the market capitalisation of ONCY?
ONCY has a market capitalisation of $86.42M on NASDAQ/NYSE.
What is the P/E ratio of ONCY?
ONCY trades at a trailing price-to-earnings (P/E) ratio of -2.67. Its price-to-book (P/B) ratio is -22.73.
Is ONCY a good stock to buy?
This page provides a data-driven analysis of ONCY, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.